| US 7,531,539 B2 | ||
| Pyrrolotriazine kinase inhibitors | ||
| Brian E. Fink, Yardley, Pa. (US); Ping Chen, Belle Mead, N.J. (US); Ashok Vinayak Purandare, Pennington, N.J. (US); and Honghe Wan, Pennington, N.J. (US) | ||
| Assigned to Bristol-Myers Squibb Company, Princeton, N.J. (US) | ||
| Filed on Aug. 08, 2007, as Appl. No. 11/835,456. | ||
| Claims priority of provisional application 60/821844, filed on Aug. 09, 2006. | ||
| Claims priority of provisional application 60/915460, filed on May 02, 2007. | ||
| Prior Publication US 2008/0045496 A1, Feb. 21, 2008 | ||
| This patent is subject to a terminal disclaimer. | ||
| Int. Cl. C07D 487/04 (2006.01); C07D 403/12 (2006.01); C07D 403/14 (2006.01); A61K 31/53 (2006.01); A61P 19/02 (2006.01); A61P 35/00 (2006.01) | ||
| U.S. Cl. 514—243 [544/183] | 10 Claims |
1. A compound of formula I
![]() R1 is hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, —OCH2cycloalkyl, arylalkyl, —COOH or —CONR12R13;
R2 and R3 are independently hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl,
substituted heteroaryl, heterocyclyl, substituted heterocyclyl, —CO alkyl, —CO substituted alkyl, —COaryl, —CO substituted
aryl, —COarylalkyl, —CO substituted heteroaryl, —CO heterocyclyl alkyl, —CO(CH2)nNR4R5, —CONR4R5, —CONHSO2R5, —NHCONHR5, —(CH2)n-aryl, —(CH2)n-substituted aryl, —(CH2)n-substituted heteroaryl, —(CH2)2(CH2)n—OH, —(CH2)2(CH2)n—NH2, —(CH2)2(CH2)n—S-alkyl, —SO2alkyl or —COCF3, two of which may be attached to the same ring carbon atom; or
R2 and R3 are taken together with the nitrogen atom to which they are attached to form an optionally substituted 4-8 membered ring,
said ring optionally containing one or more additional heteroatoms selected from —N—, —S— and —O—; said substituents on the
rings are independently selected from the group consisting of hydrogen, —OH, alkyl, substituted alkyl, cycloalkyl, substituted
cycloalkyl, alkoxy, substituted alkoxy, aryl, substituted aryl, arylalkyl, heteroaryl, substituted heteroaryl, heterocyclyl,
substituted heterocyclyl, —CONR4R5, —OCONR4R5, —CONHSO2R5, —NHCONR4R5, —NHCOalkyl, —NHCOsubstituted alkyl, —NHCOalkoxyalkyl, —NHCOalkylCOalkoxy, —NHCO(CH2)nN R4R5, NHCO(CH2)nbisphenyl, —NHCOaryl, —NHCOsubstituted aryl, —NHCO arylalkyl, —NHCOsubstituted arylalkyl, —NHCOheteroaryl, —NHCOsubstituted
heteroaryl, —NHCOheteroarylalkyl, —NHCOsubstituted heteroarylalkyl, —NHCO(CH2)n CN, —NHCOaminosulfonylalkyl, —NHCO(CH2)nNH2, —NHCOCF3, —NHSO2R4, —CH2OR4, —(CH2)n-aryl, —(CH2)n-substituted aryl, —(CH2)n-substituted heteroaryl, —(CH2)n—OH, —(CH2)nNH2, —(CH2)nS-alkyl;
R4 and R5 are independently hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, hydroxyalkyl, dihydroxyalkyl, alkoxy,
substituted alkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, halogen, cyano, amino or substituted amino;
R6 is H, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkynyl, C3-C8 cycloalkyl, C1-C5 arylalkyl, aryl, substituted aryl, heteroarylalkyl, substituted heteroarylalkyl, heteroaryl, substituted heteroaryl or C4-C8 heterocyclyl with at least one atom on the ring selected from nitrogen or oxygen atom, and each of said R6 groups optionally substituted with 1 to 3 groups selected from the group consisting of —OH, OR8, —COOR8, —NH2, —NR8R9, —CONHR8, —OCONHR8, —CONHSO2R8, —NHCONHR8, —SR8, —S(═O)R8, —SO2R8 and —SO2N R8R9;
R8 is C1-C6 alkyl, C3-C6 cycloalkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl group; said substituents on the substituted aryl
or substituted heteroaryl group are one or more hydrogen, halogen, alkyl, substituted alkyl, alkynyl, substituted alkynyl,
alkoxy, substituted alkoxy, aryl, substituted aryl, arylalkyl, substituted arylalkyl, aryloxy or substituted aryloxy;
R9 is hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl;
R12 and R13 are independently hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, hydroxyalkyl, dihydroxyalkyl, aryl,
substituted aryl, heteroaryl, substituted heteroaryl, amino and substituted amino; or
R12 and R13 are taken together with the nitrogen atom to which they are attached to form an optionally substituted 4-8 membered ring,
said ring optionally containing one or more additional heteroatoms selected from —N—, —S— and —O—; said substituents on the
ring are independently hydrogen, —OH, alkyl, substituted alkyl or hydroxyalkyl;
n is 0, 1, 2, 3 or 4;
or a pharmaceutically acceptable salt or stereoisomer thereof.
|